




ASSOCIATION
FOR MOLECULAR
PATHOLOGY

ANNUAL

2016

REPORT



2016 : Add # 83928
PUB : Add # 83928
2016 : Add # 11111
NHE : Add # 3283
Add : Add # 4949
Add : Add # 9594
Add : Add # 4838

508030400
380420800
304200000



Contents

PAGE

President's Message 3

AMP Strategic Plan 4

 Mission Statement 4

 Vision Statement 5

 Core Principles 5

2016 Board of Directors and Committee Chairs 6

International Affiliates 7

Organizational Relationships 7

Advocacy and Clinical Practice 8

Membership and AMP 2016 Annual Meeting Overview 9

International Education Initiatives 10

Financial Statement 11



Attendees at the 2016 AMP Annual Meeting.

Message

FROM THE PRESIDENT



Dear Colleagues,

The Association for Molecular Pathology is a diverse and dynamic community working to promote the highest quality molecular diagnostics and enhance patient care. We are molecular pathologists, clinical laboratorians, basic and translational scientists, technologists and trainees. While our members practice in various molecular diagnostics disciplines, we always find new ways to learn from each other and to broaden our scientific horizons.

As scientists, we recognize that collaboration and cooperation are essential to the advancement of our field. As a result, AMP is committed to fostering innovation and creating a welcoming environment for all. Whether you work in academic or community medical centers, government, or industry, I am delighted that you have chosen AMP as your professional home.

This has been a very busy year for our association. The AMP Annual Meeting remains the “premiere gathering” of molecular professionals and continues to grow in size and scope. We will also host our inaugural Global Congress next spring in Berlin, Germany. As technologies change and new challenges arise, our meetings, education resources, practice guidelines and advocacy efforts will continue to provide members and non-members alike with the critical information needed to remain at the cutting edge of our field and ensure that their patients receive the best results.

It has been my honor to serve as your President. I am proud of what we have accomplished together and I look forward to our continued successes.

Sincerely,

Charles E. Hill, MD, PhD
AMP President



Victoria M. Pratt, PhD, 2016 Program Committee Chair (left) and AMP President Charles E. Hill, MD, PhD, (right) congratulate Eric S. Lander, PhD on his 2016 Award for Excellence in Molecular Diagnostics.

Strategic Plan

MISSION • VISION • PRINCIPLES




AMP'S STRATEGIC PLAN IS DYNAMIC.

Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic goals and objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's Mission, Vision, and Core Principles.


MISSION STATEMENT

The **ASSOCIATION FOR MOLECULAR PATHOLOGY** is a not-for-profit scientific society that advances the **CLINICAL PRACTICE, SCIENCE,** and **EXCELLENCE** of molecular and genomic laboratory medicine through **EDUCATION, INNOVATION,** and **ADVOCACY** to enable highest quality health care.




2016 Past President Janina A. Longtine, MD, Executive Director Mary Steele Williams, MNA, MT(ASCP)SM and former president Karen L. Kaul, MD, PhD pictured on Capitol Hill.


I am A Molecular Professional...




"I want to use my scientific knowledge to help people."



"Personalized Medicine helps patients get the most effective treatments."



"I can create something new and paradigm-shifting that had not existed."



"I care about my patients and treat them in the way they deserve to be treated."



"Little things can make a big difference for patients."

Photos from "I am AMP (A Molecular Professional)" outreach campaign.




VISION STATEMENT

The **ASSOCIATION FOR MOLECULAR PATHOLOGY** seeks to be a global community of professionals that advances excellence in the clinical practice of molecular and genomic laboratory medicine through:

- Activities that foster **INNOVATIVE** and **TRANSFORMATIVE PATIENT CARE** and the translation of scientific discoveries into diagnostic tests and services
- **EDUCATION PROGRAMS** that promote clinical laboratory testing of high quality and utility
- **ADVOCACY** that supports the practice of molecular pathology to enhance patient care, addresses regulatory and payment issues, and facilitates the adoption of innovative laboratory testing and technologies
- Activities that facilitate knowledge transfer and **COLLABORATION** among professionals worldwide

CORE PRINCIPLES

- Quality Health Care Through **EXCELLENCE** in Clinical Molecular Testing
- Fostering the **GLOBAL COMMUNITY** of Molecular Pathology Professionals
- **COLLABORATION** to Advance Molecular Pathology
- **ADVOCACY** that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- **INNOVATION** to Transform Patient Care



Eric S. Lander, PhD, recipient of the 2016 Award for Excellence in Molecular Diagnostics addresses the annual meeting audience.

2016 AMP

BOARD OF DIRECTORS & COMMITTEE CHAIRS



2016 AMP Executive Committee: (l-r)
*Siby Sebastian, PhD, Charles E. Hill, MD, PhD,
 Federico A. Monzon, MD, Janina A. Longtine, MD,
 Andrea Ferreira-Gonzalez, PhD*

PRESIDENT
Charles E. Hill, MD, PhD
Emory University School of Medicine

**PRESIDENT-ELECT
 AND STRATEGIC OPPORTUNITIES
 COMMITTEE CHAIR (2016)**
Federico A. Monzon, MD
Castle Biosciences

**PAST PRESIDENT
 AND NOMINATING COMMITTEE CHAIR (2016)**
Janina A. Longtine, MD
*Yale School of Medicine/
 Yale New Haven Hospital*

**SECRETARY-TREASURER
 AND FINANCE COMMITTEE CHAIR (2016-2017)**
Andrea Ferreira-Gonzalez, PhD
*Virginia Commonwealth University/MCV
 Clinical Support Center*

**CLINICAL PRACTICE
 COMMITTEE CHAIR (2015-2016)**
Marina N. Nikiforova, MD
*University of Pittsburgh
 Medical Center*

**ECONOMIC AFFAIRS
 COMMITTEE CHAIR (2016)**
Samuel K. Caughron, MD
MAWD Pathology Group, PA

**MEMBERSHIP AFFAIRS
 COMMITTEE CHAIR (2014-2016)**
Nirali M. Patel, MD
UNC School of Medicine

**PROFESSIONAL RELATIONS
 COMMITTEE CHAIR (2016)**
Roger D. Klein, MD, JD
Roger D. Klein, MD, JD Consulting

PROGRAM COMMITTEE CHAIR (2016)
Victoria M. Pratt, PhD
*Indiana University
 Medical Center*

**PUBLICATION & COMMUNICATION
 COMMITTEE CHAIR (2016-2017)**
Jane Gibson, PhD
*University of Central Florida
 College of Medicine*

**TRAINING & EDUCATION
 COMMITTEE CHAIR (2016-2017)**
Annette Kim, MD, PhD
Brigham and Women's Hospital

**GENETICS SUBDIVISION
 CHAIR (2015-2016)**
Siby Sebastian, PhD
Duke University Medical Center

**HEMATOPATHOLOGY SUBDIVISION
 CHAIR (2016-2017)**
Todd W. Kelley, MD
University of Utah

**INFECTIOUS DISEASES SUBDIVISION
 CHAIR (2015-2016)**
Michael Lewinski, PhD
Roche Molecular Systems, Inc.

**INFORMATICS SUBDIVISION
 CHAIR (2015-2016)**
Alexis B. Carter, MD
Children's Healthcare of Atlanta

**SOLID TUMORS SUBDIVISION
 CHAIR (2016-2017)**
Laura J. Tafe, MD
Dartmouth-Hitchcock Medical Center

**INVITED GUEST
 INTERNATIONAL AFFAIRS
 COMMITTEE CHAIR (2016)**
Lei Po (Chris) Wong, PhD
University of Macau, Hong Kong

EXECUTIVE DIRECTOR
**Mary Steele Williams,
 MNA, MT(ASCP)SM, CAE**

**2016 AMP
 Board of Directors: (l-r)**
*Alexis B. Carter, MD,
 Charles E. Hill, MD, PhD,
 Siby Sebastian, PhD,
 Victoria M. Pratt, PhD,
 Janina A. Longtine, MD,
 Marina N. Nikiforova, MD,
 Jane Gibson, PhD,
 Samuel K. Caughron, MD,
 Nirali M. Patel, MD,
 Laura J. Tafe, MD,
 Andrea Ferreira-Gonzalez, PhD,
 Lei Po (Chris) Wong, PhD,
 Todd W. Kelley, MD,
 Federico A. Monzon, MD,
 Roger D. Klein, MD, JD*



Affiliations

INTERNATIONAL AFFILIATES

The Hong Kong Society for Molecular Diagnostic Sciences
 The Korean Society for Laboratory Medicine
 The Molecular Pathology Association of India
 The German Society of Pathology

ORGANIZATIONAL RELATIONSHIPS

AMP maintains **MEMBERSHIP** in the following organizations:

- Association of Pathology Chairs (APC) Pathology Roundtable
- Cancer Leadership Council (CLC)
- Federation of American Societies for Experimental Biology (FASEB)
- Foundation for the National Institutes of Health Biomarkers Consortium
- Global Alliance for Genomic Medicine
- Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
- Intersociety Pathology Council (IPC)
- Personalized Medicine Coalition (PMC)

AMP maintains productive organizational **RELATIONSHIPS** with the following groups:

- Cooperating Society of the American Board of Pathology (ABP)
- Steering Committee, NIST Genome in a Bottle Consortium
- Associate Member of the Intersociety Council for Pathology Information (ICPI)
- Sponsor of the National Academy of Medicine Roundtable on Genomics and Precision Health
- Representative to the CAP Molecular Oncology Committee
- Representative to the Pathology Coding Caucus
- Liaison to/from the American Society of Cytopathology
- Liaisons to/from many other professional societies on a project-specific basis



Expert Panelists from CAP, IASLC and AMP at the February 2016 working group meeting to revise the 2013 Lung Biomarker Guideline.



Advancing

MOLECULAR MEDICINE

AMP ADVOCATES for excellence in molecular testing from the lab to the legislature. AMP's advocacy efforts focus on advancing the field and practice of molecular pathology by informing and influencing public policy. AMP's clinical and scientific affairs initiatives aim to transform patient care through **INNOVATION**.

ADVOCACY

In 2016, AMP launched **The ChAMPion**, a newsletter devoted exclusively to public policy topics, participated in several advocacy events, and issued **32 POSITION STATEMENTS** and letters on issues such as:

- Reimbursement for Molecular Pathology and Genomic Sequencing Procedures
- Protecting Access to Medicare Act (PAMA)
- Local Coverage Determinations for Molecular Procedures
- Molecular Testing for Zika Virus
- Common Rule
- Proposed FDA Oversight of NGS-Based Diagnostics & LDPs
- Protecting the Genetic Information Nondiscrimination Act
- *And Much More*

INNOVATION & IMPROVED PATIENT CARE

In 2016, over **100 MEMBER VOLUNTEERS** worked on multiple AMP efforts to foster excellence in clinical practice and patient care. These efforts included the launch of public open comment collection for the multidisciplinary lung cancer molecular biomarkers practice guideline and the publication of two major reports:

The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology

J Mol Diagn. 2016 Sep;18(5):605-619

Emerging and Future Applications of Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry in the Clinical Microbiology Laboratory: A Report of the Association for Molecular Pathology

J Mol Diagn. 2016 Nov;18(6):789-802



2016 President-Elect Federico A. Monzon, MD visits the offices of Texas legislators to discuss patient care and regulatory and reimbursement issues facing the molecular diagnostics industry.



Roger D. Klein MD, JD, Janina A. Longtine, MD, and Sheri Bale, PhD pose near Capitol Hill following AMP's congressional briefing on Laboratory Developed Procedures.

Membership

AND ANNUAL MEETING OVERVIEW




AMP ended the year with continued membership growth, rising from 2,354 in 2015 to **2,370** in 2016. Indicators suggest that the growth will continue for the coming years. AMP members can be found in **47 COUNTRIES**.

Attendance continued to be strong at the **2016 ANNUAL MEETING**. We welcomed over **2,000** attendees and approximately **1,800** exhibitors representing more than **200** companies.


YEAR	LOCATION	SCIENTIFIC ATTENDEES
2008	GAYLORD TEXAN, TX	969
2009	GAYLORD PALMS, FL	1,071
2010	SAN JOSE, CA	1,266
2011	GAYLORD TEXAN, TX	1,343
2012	LONG BEACH, CA	1,674
2013	PHOENIX, AZ	1,720
2014	WASHINGTON, DC	1,900
2015	AUSTIN, TX	2,059
2016	CHARLOTTE, NC	2,029



AMP MEMBERS WORK IN:



AMP MEMBERS BY DEGREE:






International

EDUCATION INITIATIVES

AMP's educational initiatives continue to reach a global audience. In 2016, AMP collaborated on molecular diagnostic-related conferences in Chandigarh, **INDIA**; Seoul, **KOREA**; and Montesilvano, **ITALY**.

AMP hosted its second **INTERNATIONAL SHOWCASE** event at the AMP 2016 Annual Meeting. In addition, the inaugural **2017 GLOBAL CONGRESS** on Molecular Pathology will be held in Berlin, **GERMANY**, April 3-5, 2017.






Financial

S T A T E M E N T

AMP's fiscal footing is solid, allowing it to dedicate significant resources to each of its strategic initiatives.



STRATEGIC INITIATIVE REVENUE OVER EXPENSES	2016	2015	2014
Advocacy	\$ (426,435)	\$ (425,166)	\$ (586,685)
Communications & Outreach	\$ (174,649)	\$ (206,633)	\$ (183,330)
Education	\$ 2,299,693	\$ 2,800,434	\$ 1,985,130
Innovation & Improved Patient Care	\$ (290,237)	\$ (280,556)	\$ (250,085)
Membership & Management Services	\$ (32,781)	\$ (502,766)	\$ (573,771)
EXCESS REVENUE OVER EXPENSES	\$ 1,375,591	\$ 1,385,313	\$ 391,259



ASSOCIATION
FOR MOLECULAR
PATHOLOGY

9650 Rockville Pike
Suite E205
Bethesda, MD 20814

CHAMP



www.amp.org